Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.
Fiche publication
Date publication
novembre 2022
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
Tous les auteurs :
Puéchal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, Karras A, Blanchard-Delaunay C, Quéméneur T, Aouba A, Aumaître O, Cottin V, Hamidou M, Ruivard M, Cohen P, Mouthon L, Guillevin L, Ravaud P, Porcher R, Terrier B,
Lien Pubmed
Résumé
Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.
Mots clés
Male, Humans, Middle Aged, Rituximab, therapeutic use, Peroxidase, Antibodies, Antineutrophil Cytoplasmic, Myeloblastin, Granulomatosis with Polyangiitis, drug therapy, Induction Chemotherapy, Cyclophosphamide, therapeutic use, Coloring Agents
Référence
JAMA Netw Open. 2022 11 1;5(11):e2243799